Eisai Company Ltd (ESALF)

$69.75 0.00 (0.00%)

9:38 EDT ESALF Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 14

Day's Range -

52-Week Range $52.42 - $76.96

Dividend & Yield N/A (N/A)

ESALF Stock Predictions, Articles, and Eisai Company Ltd News

From the Web

Biogen stock gains on FDA briefing docs on Alzheimer’s drug

From Seeking Alpha Jun 7, 2023

The FDA commented on Biogen's (BBIB) and Eisai's (ESALF) (ESAIY), Alzheimer's therapy, Leqembi, sending the shares of the U.S. biotech higher Wednesday. Read more here.

Catalyst maintains FY23 revenue outlook

From Seeking Alpha Jun 1, 2023

Catalyst Pharmaceuticals (CPRX) reaffirmed its full-year 2023 total revenue and products outlook. Read more here

Prothena stock adds ex-FDA neuro chief Billy Dunn to board (NASDAQ:PRTA)

From Seeking Alpha May 17, 2023

Alzheimer's drug developer Prothena (PRTA) announced Tuesday that Billy Dunn, who previously led the FDA's Office of Neuroscience, is joining its board. Read more here.

Biogen’s new Alzheimer’s drug to raise Medicare costs (NASDAQ:BIIB)

From Seeking Alpha May 14, 2023

If broadly covered, Leqembi, the new Alzheimer&#39;s drug from Biogen (BIIB) and Eisai (ESALF) (ESAIY), could add $2B - $5B costs to Medicare annually. Read more here.

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

From Benzinga May 10, 2022

FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer

From Benzinga Mar 22, 2022